Royal Bank of Canada
RNAZ icon

Royal Bank of Canada’s TransCode Therapeutics RNAZ Stock Holding History

Royal Bank of Canada’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8
Closed – – 7739
2026
Q1 		$0 Hold
8
– – ﹤0.01% 7607
2025
Q4 		$0 Hold
8
– – ﹤0.01% 7564
2025
Q3 		$0 Hold
8
– – ﹤0.01% 7468
2025
Q2 		$0 Sell
8
-1
-11% -$9 ﹤0.01% 7300
2025
Q1 		$0 Buy
+9
New +$1.15K ﹤0.01% 7182
2024
Q3 		– Hold
0
– – – 7348
2024
Q2 		– Hold
0
– – – 7460
2024
Q1 		– Hold
0
– – – 7507
2023
Q4 		– Hold
0
– – – 7510
2023
Q3 		– Hold
0
– – – 7499
2023
Q2 		– Hold
0
– – – 7602
2022
Q4 		– Hold
0
– – – 7638
2022
Q3 		– Hold
0
– – – 7785
2022
Q1 		– Hold
0
– – – 7969
2021
Q4 		– Hold
0
– – – 7854

Other funds holding RNAZ

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Royal Bank of Canada's RNAZ Position: Q2 2026 in Review

Royal Bank of Canada sold out of TransCode Therapeutics (RNAZ) in Q2 2026, closing a stake of 8 shares.

Royal Bank of Canada first reported a position in RNAZ in Q1 2025 and held it in 5 quarters. The position peaked at $0 in Q1 2026. 8 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

  • Royal Bank of Canada reported no remaining TransCode Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 8 TransCode Therapeutics shares in Q2 2026.
  • Royal Bank of Canada first reported a position in TransCode Therapeutics in Q1 2025 and held it in 5 quarters.
  • Royal Bank of Canada's TransCode Therapeutics position peaked at $0 in Q1 2026.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.